Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 6/20 | 0.51 |
| ▸ | JAK3 | P52333 | 3/20 | 0.49 |
| ▸ | JAK1 | P23458 | 2/20 | 0.49 |
| ▸ | JAK2 | O60674 | 1/20 | 0.49 |
| ▸ | EGFR | P00533 | 5/20 | 0.47 |
| ▸ | BRD4 | O60885 | 6/20 | 0.46 |
| ▸ | BTK | Q06187 | 3/20 | 0.43 |
| ▸ | ITK | Q08881 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17916029 | 0.87 | SYK (0.54) | SYKJAK3JAK1JAK2EGFR | |
| SCHEMBL270789 | 0.84 | SYK (0.51) | SYKJAK3JAK1JAK2EGFR | |
| SCHEMBL305864 | 0.83 | JAK1 (0.59) | SYKJAK3JAK1JAK2BRD4 | |
| SCHEMBL305045 | 0.81 | SYK (0.78) | SYKJAK3EGFRBTKITK | |
| SCHEMBL12321383 | 0.81 | SYK (0.55) | SYKJAK3JAK1JAK2EGFR | |
| SCHEMBL301484 | 0.80 | EGFR (0.57) | SYKJAK3JAK2EGFRBTK | |
| SCHEMBL12111163 | 0.79 | BRD4 (0.59) | SYKJAK3EGFRBRD4BTK | |
| SCHEMBL300797 | 0.79 | SYK (0.53) | SYKJAK3JAK1JAK2EGFR | |
| SCHEMBL305410 | 0.79 | SYK (0.59) | SYKJAK3JAK2EGFRBRD4 | |
| SCHEMBL301912 | 0.78 | CTSC (0.57) | SYKBTKITK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1951684-B1 | BI-ARYL META-PYRIMIDINE INHIBITORS OF KINASES | TARGEGEN INC (US) | 2016-07-13 | — | — | EP | disclosed |
| US-8133900-B2 | Use of bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2012-03-13 | — | — | US | disclosed |
| US-7825246-B2 | Bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2010-11-02 | — | — | US | disclosed |
| WO-2010017122-A2 | METHODS OF TREATING THALASSEMIA | TARGEGEN INC. (US) | 2010-02-11 | — | — | WO | disclosed |
| US-7528143-B2 | Bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2009-05-05 | — | — | US | disclosed |
| US-20070259904-A1 | Bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2007-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070259904-A1 | Bi-aryl meta-pyrimidine inhibitors of kinases | JAK2, TYK2, JAK3 | SYK 281/4885JAK3 3/4885JAK1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.